Key Highlights
- H1 2026 Revenue rose 45% to £3.2 million, while underlying operating costs fell 15% to £7.8 million.
- The underlying operating loss narrowed more than 25% to £4.9 million from £6.9 million.
- Creo raised approximately £5.5 million via a share placing in May 2026, alongside a £2 million convertible Loan note.
- A proposed sale of its 49% stake in Spanish joint venture Creo Medical S.L. remains pending, subject to Due Diligence .
- FY2026 guidance points to 50-60% revenue growth alongside roughly 15% lower underlying operating costs.
LSE-listed Creo Medical grew first-half 2026 revenue 45% to £3.2m and cut underlying operating costs 15%, narrowing losses, after outsourcing Manufacturing and raising £5.5m. A near-term sale of its European joint venture and going-concern caveats remain live issues.
Creo Medical Group (LSE:CREO), the Chepstow-based developer of minimally invasive electrosurgical devices, has delivered a first half in which faster sales growth and a leaner cost base moved together. The AIM-listed company's H1-26 trading update, published on 28 July 2026, showed revenue up 45% year-on-year alongside a 15% reduction in underlying operating costs, translating into a narrower operating loss. For a Business that has spent years burning cash to build its Speedboat and MicroBlate endoscopy platforms, the combination of accelerating Demand and tighter spending is the clearest signal yet that management's stated path towards sustainable Cash Flow is more than aspiration.
What Happened
Creo told investors that revenue for the six months to 30 June 2026 reached £3.2 million, up 45% from £2.2 million in H1-25. Underlying operating costs fell to £7.8 million from £9.1 million, a 15% reduction, while the underlying operating loss narrowed to £4.9 million from £6.9 million, an improvement of more than 25%. The update followed months of restructuring: in April the group disposed of and outsourced its manufacturing operations, and in May it raised approximately £5.5 million through a share placing at 15p, a 31.9% premium to the prior closing price, alongside a £2 million convertible loan note from the Development Bank of Wales and a proposed sale of its 49% interest in Spanish joint venture Creo Medical S.L. (CME). Chief executive Craig Gulliford said the group had "delivered a strong first half, with the actions taken during the period strengthening the foundations of the Group," having "improved our operating platform and established a materially lower cost base."
Why It Matters
The result matters because it addresses two criticisms frequently levelled at growth medtechs on AIM: that revenue growth fails to translate into Operating Leverage , and that cash is consumed faster than the commercial story justifies. Creo's H1 figures show both metrics moving together rather than trading off. The manufacturing outsourcing deal, completed in the second quarter, appears to be the principal driver of the cost reduction, removing a fixed-cost base that had weighed on the group since it began in-house production. Combined with continued adoption of Speedboat and the newer MicroBlate devices, the update supports the view that Creo's commercial platform is scaling faster than its cost base — a dynamic that, if sustained, would shorten the path to breakeven.
Latest Financial and Operational Performance
Full-year 2025 results, published alongside the May placing, showed revenue of £6.0 million, up 50% on FY24's £4.0 million, with second-half growth accelerating to 58%. Gross Margin on continuing operations was 40.0%, down from 47.5% a year earlier. The underlying operating loss for FY25 fell 38.5% to £13.7 million, though statutory operating loss on continuing operations was £17.8 million, and net cash used in operations was £19.1 million, better than £22.2 million in FY24. Cash stood at £12.4 million at end-2025, up from £8.7 million a year earlier, but had fallen to £7.4 million by 30 June 2026 ahead of the fundraise landing. The FY25 accounts carried a going-concern qualification, with directors stating that "without additional funding, the Group would be unable to meet its liabilities as they fall due within the next 12 months," while expecting to secure further funding — since partly addressed by the placing, the loan note and the pending CME disposal. Guidance for FY26 revenue growth was raised from 40–60% to 50–60%, alongside cost reduction of around 15%.
Key Numbers
- H1-26 revenue: £3.2m, up 45% (H1-25: £2.2m)
- Underlying operating costs H1-26: £7.8m, down 15% (H1-25: £9.1m)
- Underlying operating loss H1-26: £4.9m, down over 25% (H1-25: £6.9m)
- Cash at 30 June 2026: £7.4m (31 Dec 2025: £12.4m)
- FY25 revenue: £6.0m, up 50% (FY24: £4.0m); gross margin 40.0%
- FY25 underlying operating loss: £13.7m, down 38.5%; net cash used in operations £19.1m
- May 2026 placing: £5.5m raised at 15p/share, plus £2m convertible loan note (Development Bank of Wales)
- FY26 guidance: revenue growth 50–60%, underlying operating costs down approximately 15%
Growth Opportunities
Creo's growth case rests on wider adoption of its Kamaptive energy platform, which combines microwave and bipolar radiofrequency energy in devices for minimally invasive tissue cutting, coagulation and ablation across gastroenterology, pulmonology, urology and surgery. Speedboat, its flagship submucosal dissection device, continues to gain traction in NHS and international hospitals, while MicroBlate Flex has now been used in more than 100 clinical cases and MicroBlate Fine in around 50. The group has flagged a strong order book heading into the third quarter and points to its planned Bipolar product range, targeted for 2027 launch, as a further driver. The proposed CME stake sale, if completed, would crystallise value from the minority interest while preserving a European distribution relationship, freeing Capital for commercial expansion.
Risks Investors Should Know
The most material risk remains funding. Creo's FY25 accounts carried an explicit going-concern qualification, and while the placing, loan note and prospective CME proceeds provide a bridge, the company remains loss-making, with cash more than halving in H1 2026 alone. The CME sale is non-binding and subject to due diligence, pre-emption, documentation and financing approval, so completion and timing are not guaranteed. Gross margin has declined year-on-year, and further financing cannot be ruled out if targets slip, diluting existing shareholders. Execution risk around the newly outsourced manufacturing model, and the wider competitive and reimbursement landscape in endoscopic devices, also bear watching.
What to Watch Next
Investors should track completion of the CME stake sale, expected within roughly three months of the May announcement, and whether it lands at the anticipated valuation. The pace of cash burn against the £7.4 million June cash position will determine whether further financing is needed. Continued case growth for MicroBlate and Speedboat's commercial rollout, alongside progress on the Bipolar range, will indicate whether H1 momentum can be sustained.
Outlook
Creo Medical's first-half update offers tangible evidence that restructuring is bearing fruit, with revenue growth and cost discipline improving simultaneously. Yet the going-concern language attached to its FY25 accounts and the still-pending CME disposal are reminders that the underlying financial position remains fragile. The next two quarters, encompassing the CME sale outcome and continued execution on cost and revenue targets, will show whether this is the inflection point management has long promised.






Please wait processing your request...